Company Filing History:
Years Active: 2020-2022
Title: Christopher Herring: Innovator in Targeted Protein Degradation
Introduction
Christopher Herring is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of biotechnology, particularly in the area of targeted protein degradation. With a total of 2 patents to his name, Herring is recognized for his innovative approaches to controlling polypeptide sequences.
Latest Patents
Herring's latest patents focus on a method of controlling the level of a polypeptide sequence. This involves administering a polypeptide sequence fused to a ubiquitin targeting protein that comprises a minimal degron structural motif. Notably, the polypeptide sequence includes a chimeric antigen receptor, making this invention particularly useful in cell and gene therapy where the activity of the chimeric antigen receptor needs to be regulated.
Career Highlights
Christopher Herring is currently associated with GlaxoSmithKline Intellectual Property Development Limited. His work at this esteemed company has allowed him to explore and develop groundbreaking technologies in the realm of protein degradation.
Collaborations
Herring has collaborated with notable colleagues, including Lewis Lee Brayshaw and Michael Menteith Hann. These partnerships have further enriched his research and development efforts.
Conclusion
Christopher Herring stands out as an influential inventor in the biotechnology sector, particularly with his advancements in targeted protein degradation. His contributions are paving the way for innovative therapies in medicine.